Antibody response correlates with severity of infection.Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. With a linear mixed model, neutralizing antibody titer was shown to peak bet...
Antibody response correlates with severity of infection.Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. With a linear mixed model, neutralizing antibody titer was shown to peak between week 5 and week 8 after onset and to decline thereafter, with a half-life of 6.4 weeks. Patients with a longer illness showed a lower neutralizing antibody response than patients with a shorter illness duration (p = 0.008). When early responders were compared with most patients, who seroconverted on and after week 3 of illness, the small proportion (17.4%) of early responders (antibody detectable within 2 weeks) had a higher death rate (29.6% vs. 7.8%) (Fisher exact test, p = 0.004), had a shorter survival time of 60 years of age (Fisher exact test, p = 0.01). Our findings have implications for understanding the pathogenesis of SARS and for SARS vaccine research and development.
Antibody response correlates with severity of infection.Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. With a linear mixed model, neutralizing antibody titer was shown to peak between week 5 and week 8 after onset and to decline thereafter, with a half-life of 6.4 weeks. Patients with a longer illness showed a lower neutralizing antibody response than patients with a shorter illness duration (p = 0.008). When early responders were compared with most patients, who seroconverted on and after week 3 of illness, the small proportion (17.4%) of early responders (antibody detectable within 2 weeks) had a higher death rate (29.6% vs. 7.8%) (Fisher exact test, p = 0.004), had a shorter survival time of 60 years of age (Fisher exact test, p = 0.01). Our findings have implications for understanding the pathogenesis of SARS and for SARS vaccine research and development.
1. Drosten C , Gunther S , Preiser W , van der Werf S , Brodt HR , Becker S , Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med . 2003 ; 348 : 1967 – 76 . 10.1056/NEJMoa030747 12690091
2. Ksiazek TG , Erdman D , Goldsmith CS , Zaki SR , Peret T , Emery S , A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med . 2003 ; 348 : 1953 – 66 . 10.1056/NEJMoa030781 12690092
3. Guan Y , Zheng BJ , He YQ , Liu XL , Zhuang ZX , Cheung CL , Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science . 2003 ; 302 : 276 – 8 . 10.1126/science.1087139 12958366
4. Yang ZY , Kong WP , Huang Y , Roberts A , Murphy BR , Subbarao K , A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature . 2004 ; 428 : 561 – 4 . 10.1038/nature02463 15024391
6. Booth CM , Matukas LM , Tomlinson GA , Rachlis AR , Rose DB , Dwosh HA , Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA . 2003 ; 289 : 2801 – 9 . 10.1001/jama.289.21.JOC30885 12734147
8. Ding Y , He L , Zhang Q , Huang Z , Che X , Hou J , Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol . 2004 ; 203 : 622 – 30 . 10.1002/path.1560 15141376
12. Yu IT , Li Y , Wong TW , Tam W , Chan AT , Lee JH , Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med . 2004 ; 350 : 1731 – 9 . 10.1056/NEJMoa032867 15102999
13. Peiris JS , Yuen KY , Osterhaus AD , Stohr K . The severe acute respiratory syndrome. N Engl J Med . 2003 ; 349 : 2431 – 41 . 10.1056/NEJMra032498 14681510
15. Centers for Disease Control and Prevention . Severe acute respiratory syndrome—Taiwan, 2003. MMWR Morb Mortal Wkly Rep . 2003 ; 52 : 461 – 6 . 12807078
16. Lai EK , Deif H , LaMere EA , Pham DH , Wolff B , Ward S , Severe acute respiratory syndrome: quantitative assessment from chest radiographs with clinical and prognostic correlation. AJR Am J Roentgenol . 2005 ; 184 : 255 – 63 . 15615985
17. Hosmer D , Lemeshow S . Applied logistic regression. 2nd ed. New York: Wiley; 2000 .
18. Verbeke G , Molenberghs G . Linear mixed models for longitudinal data. New York: Springer-Verlag; 2000 .
19. Han DP , Kim HG , Kim YB , Poon LL , Cho MW . Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology . 2004 ; 326 : 140 – 9 . 10.1016/j.virol.2004.05.017 15262502
22. Markowitz LE , Sepulveda J , Diaz-Ortega JL , Valdespino JL , Albrecht P , Zell ER , Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. N Engl J Med . 1990 ; 322 : 580 – 7 . 10.1056/NEJM199003013220903 2304505
23. Cutts FT , Nyandu B , Markowitz LE , Forsey T , Zell ER , Othepa O , Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in 3.5-month-old infants, and of medium- or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasa, Zaire. Vaccine . 1994 ; 12 : 1311 – 6 . 10.1016/S0264-410X(94)80057-7 7856296
24. Maldonado YA , Pena-Cruz V , de la Luz Sanchez M , Logan L , Blandon S , Cantwell MF , Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. J Infect Dis . 1997 ; 175 : 545 – 53 . 10.1093/infdis/175.3.545 9041324
26. So LK , Lau AC , Yam LY , Cheung TM , Poon E , Yung RW , Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet . 2003 ; 361 : 1615 – 7 . 10.1016/S0140-6736(03)13265-5 12747883
27. Cheung TM , Yam LY , So LK , Lau AC , Poon E , Kong BM , Effectiveness of noninvasive positive pressure ventilation in the treatment of acute respiratory failure in severe acute respiratory syndrome. Chest . 2004 ; 126 : 845 – 50 . 10.1378/chest.126.3.845 15364765
29. Wong CK , Lam CW , Wu AK , Ip WK , Lee NL , Chan IH , Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol . 2004 ; 136 : 95 – 103 . 10.1111/j.1365-2249.2004.02415.x 15030519
30. Jiang Y , Xu J , Zhou C , Wu Z , Zhong S , Liu J , Characterization of cytokine and chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med . 2005 ; 171 : 850 – 7 . 10.1164/rccm.200407-857OC 15657466
31. Huang K , Su I , Theron M , Wu YC , Lai SK , Liu CC , An interferon-gamma-related cytokine storm in SARS patients. J Med Virol . 2005 ; 75 : 185 – 94 . 10.1002/jmv.20255 15602737
32. Ichinohe T , Watanabe I , Ito S , Fujii H , Moriyama M , Tamura S , Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol . 2005 ; 79 : 2910 – 9 . 10.1128/JVI.79.5.2910-2919.2005 15709010
33. Cheng Y , Wong R , Soo Y , Wong WS , Lee CK , Ng MH , Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis . 2005 ; 24 : 44 – 6 . 10.1007/s10096-004-1271-9 15616839
34. Barrett AD , Gould EA . Antibody-mediated early death in vivo after infection with yellow fever virus. J Gen Virol . 1986 ; 67 : 2539 – 42 . 10.1099/0022-1317-67-11-2539 3783130
36. Hohdatsu T , Yamada M , Tominaga R , Makino K , Kida K , Koyama H . Antibody-dependent enhancement of feline infectious peritonitis virus infection in feline alveolar macrophages and human monocyte cell line U937 by serum of cats experimentally or naturally infected with feline coronavirus. J Vet Med Sci . 1998 ; 60 : 49 – 55 . 10.1292/jvms.60.49 9492360
37. Takada A , Kawaoka Y . Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol . 2003 ; 13 : 387 – 98 . 10.1002/rmv.405 14625886
38. Hohdatsu T , Yamato H , Ohkawa T , Kaneko M , Motokawa K , Kusuhara H , Vaccine efficacy of a cell lysate with recombinant baculovirus-expressed feline infectious peritonitis (FIP) virus nucleocapsid protein against progression of FIP. Vet Microbiol . 2003 ; 97 : 31 – 44 . 10.1016/j.vetmic.2003.09.016 14637036
39. Greenough TC , Babcock GJ , Roberts A , Hernandez HJ , Thomas WD Jr , Coccia JA , Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis . 2005 ; 191 : 507 – 14 . 10.1086/427242 15655773
40. ter Meulen J , Bakker AB , van den Brink EN , Weverling GJ , Martina BE , Haagmans BL , Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet . 2004 ; 363 : 2139 – 41 . 10.1016/S0140-6736(04)16506-9 15220038
※ AI-Helper는 부적절한 답변을 할 수 있습니다.